

Product Data Sheet

Product Name: LATS-IN-2

Cat. No.: GC81778

Chemical Properties

Cas. No. 2248728-49-4

Formula $C_{15}H_{16}N_6$ M.Wt 280.33

Solubility DMSO: 100 mg/mL (356.72 mM; Need ultrasonic) Storage Store at 4°C, sealed storage, away from moisture

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

LATS-IN-2 is an efficiently acting LATS (large tumor suppressor kinase) inhibitor. LATS-IN-2 shows potent inhibitory activity against LATS1 with an IC_{50} value of 1.3 nM. LATS-IN-2 suppresses the

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

phosphorylation of YAP by inhibiting LATS kinase activity. LATS-IN-2 increases the thickness of the epidermis in mice. LATS-IN-2 can be used for the study of ocular diseases such as limbal stem cell deficiency and corneal endothelial dysfunction [1].

In Vivo, LATS-IN-2 (Compound 133) (0.2-2 mg/mL, topical application, twice daily, 2 days) significantly up-regulates the expression of YAP target gene Cyr61 in a dose-dependent manner in the skin around the wound edge of mice with full-thickness excisional wounds [1].

In Vitro, LATS-IN-2 (Compound 133) (9 μ M, 1 h) dramatically reduces the phosphorylation level of YAP (Ser127) in human HaCaT keratinocytes [1]. LATS-IN-2 (1-20 μ M, 12-16 days) promotes 100- to 2200-fold expansion of seeded LSCs, and maintains p63 α -positive cells in the expanded population [1]. LATS-IN-2 (0.5-25 μ M, 1-2 weeks) induces strong proliferation of human CECs [1].

References:

[1]. BEHNKE, Dirk, et al. 6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS. WO 2018/198077 A2. World Intellectual Property Organization (WIPO). 01 November 2018.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA